NYXH Stock Analysis

Understanding the Fundamentals of Nyxoah (NYXH): An Educational StockValueFinder Research Review

This article provides a comprehensive, educational breakdown of Nyxoah (NYXH), a company operating within the Healthcare sector and specifically the Medical Devices industry. This report is an automated StockValueFinder review designed to teach investors how to interpret specific financial metrics and understand the quantitative framework used to assess corporate health. This is not a recommendation to trade, but rather an educational deep dive into the data points associated with this ticker.

Overview of Nyxoah (NYXH)

Nyxoah is a medical device company. In the complex landscape of healthcare technology, companies often require significant capital to navigate regulatory hurdles, research and development, and market penetration. When evaluating a company in the medical device industry, an analyst must look past the potential of the technology and focus on the underlying financial stability.

Currently, Nyxoah (NYXH) is trading at a recent price of $1.46. While the price per share is a common metric used by retail traders, professional fundamental analysis focuses on what that price represents in relation to the company's earnings, debt, and capital efficiency. In this review, we will dissect the specific metrics provided by the StockValueFinder system to see how Nyxoah measures up against standard financial benchmarks.

Why the StockValueFinder Score Matters

The StockValueFinder score for Nyxoah is 33%, resulting in a rating of AVOID. It is vital for students of the market to understand what this score signifies. The score is a composite metric derived from various fundamental tests, including profitability, debt management, and valuation.

A high score (typically approaching 100%) indicates that a company has passed most of the quantitative screens for stability and value. A low score, such as Nyxoah's 33%, indicates that the company failed multiple critical tests. In this case, the "AVOID" rating is triggered by failures in several core areas of financial health. When you see a low score, it serves as an educational signal to look closely at the specific failures—such as negative earnings or poor capital returns—to understand why the risk profile is elevated.

EPS Strength and Consistency

Earnings Per Share (EPS) is a fundamental metric representing the portion of a company's profit allocated to each outstanding share of common stock. Consistency in EPS is often used as a proxy for a company's ability to generate real economic value for its shareholders.

For Nyxoah, the EPS test resulted in a "Did not pass" status. While the system did not supply the exact historical EPS values for this review, the failure of the test indicates that the company's earnings do not meet the required thresholds for strength or consistency.

**Educational Example:** To evaluate other stocks, consider this: An investor looking for stability might seek a company with a consistent, positive EPS growth rate over several years. If Company A earns $2.00 per share every year, it shows predictability. If Company B has an EPS that swings wildly between +$1.00 and -$0.50, it demonstrates high volatility and uncertainty. Because Nyxoah failed this test, it suggests the company is likely not currently generating the stable earnings required by this specific screening model.

ROIC and Capital Efficiency

Return on Invested Capital (ROIC) is one of the most critical metrics for assessing how effectively a company uses its money to generate additional profit. It measures the return a company generates on all the capital it has deployed (both debt and equity).

Nyxoah reports an ROIC of -98.81%.

In professional financial analysis, the range for ROIC is quite clear

* **Strong/Attractive Range:** Generally, a healthy company seeks an ROIC of 10% or higher. This indicates the company is creating value above its cost of capital. * **Weak/Risky Range:** An ROIC that is zero or negative is a significant red flag, as it means the company is actually destroying value by consuming capital without producing a proportional return.

Nyxoah failed the ROIC test because -98.81% is significantly below the 10% threshold.

**Educational Example:** Imagine two companies, X and Y. Company X has an ROIC of 15%. This means for every $100 it invests in its business, it generates $15 in profit. Company Y has an ROIC of 4%. While still positive, Company Y is using its capital much less efficiently than Company X. When the ROIC is negative, as it is with Nyxoah, the company is effectively losing money on every dollar it puts to work.

Interest Coverage and Financial Safety

Interest coverage is a solvency ratio that measures how easily a company can pay the interest expenses on its outstanding debt. This is a crucial metric for assessing "purchasing-power risk" and the danger of insolvency during periods of high interest rates or economic contraction.

The StockValueFinder system recorded that Nyxoah "Did not pass" the interest coverage test. While an exact multiplier was not provided, we know that the company fell below the preferred benchmark.

* **Strong/Attractive Range:** StockValueFinder prefers an interest coverage ratio of 6 or higher. This provides a significant "cushion" for the company to meet its obligations even if earnings fluctuate. * **Weak/Risky Range:** A ratio below 1.5 or 2 is often considered dangerous, as it means the company's earnings are barely sufficient to cover its interest payments.

**Educational Example:** If a company has an interest coverage of 8x, it means its earnings are eight times larger than its interest obligations. This is a healthy position. If a company has an interest coverage of 2x, it only has twice as much money as it needs to pay the bank; a small dip in revenue could make them unable to pay their interest, leading to potential default.

Debt Payback and Balance Sheet Discipline

Debt payback refers to the estimated time it would take for a company to pay back its total debt using its current cash flows. This metric helps investors understand the long-term sustainability of a company's leverage.

Nyxoah shows a debt payback value of -0.24 years.

Interestingly, the system marked this specific test as "Passed." This may seem counterintuitive given the negative number, but we must adhere strictly to the supplied data.

* **Strong/Attractive Range:** StockValueFinder prefers a debt payback of 3 years or less. * **Weak/Risky Range:** A debt payback of 7 years or more is often viewed as a sign of heavy, potentially unmanageable long-term debt.

**Educational Example:** If a company has 1.5 years of debt payback, it is in an attractive position because it can clear its obligations quickly using its current operations. If a company has 10 years of debt payback, it is highly reliant on long-term stability to avoid a debt crisis.

P/E Ratio and Valuation Discipline

The Price-to-Earnings (P/E) ratio is a valuation metric that compares the current share price to its per-share earnings. It is used to determine if a stock is "expensive" or "cheap" relative to its profits.

Nyxoah has a P/E ratio of -0.60. The system marked the P/E valuation test as "Passed."

* **Strong/Attractive Range:** For valuation discipline, StockValueFinder prefers a P/E of 15 or lower. * **Weak/Risky Range:** A very high P/E (such as 50 or 100) may indicate the stock is overvalued, unless accompanied by extreme growth.

**Educational Example:** A P/E of 8 is often considered more "value-oriented" than a P/E of 40, because you are paying less for every dollar of earnings the company produces. However, when a P/E is negative (as it is with Nyxoah at -0.60), it typically indicates that the company has no earnings (it is losing money). In such cases, traditional P/E valuation becomes a mathematical abstraction rather than a direct measure of value.

Moving Average Trend and Entry Timing

Technical indicators like moving averages are used to identify the direction of a stock's price trend. This is intended for timing discipline—helping an investor decide *when* to look at a stock—rather than proving that a stock is fundamentally sound.

For Nyxoah, the moving average signal is "INSUFFICIENT DATA" and the entry signal is "N/A."

When data is insufficient, it means there has not been enough recent price movement or historical data available to the system to establish a reliable trend line. Without a clear signal, an analyst cannot determine if the stock is in an uptrend or a downtrend.

Regarding entry points

* **Limit Buy Idea:** N/A * **Pullback Zone:** N/A * **Risk Stop / Trend Risk Level:** N/A

These fields are intended to provide educational reference levels for where an investor might theoretically place orders. Since they are marked N/A, there are no calculated levels for Nyxoah at this time.

Overall Financial Strengths and Weaknesses

Based on the data provided, we can summarize the financial profile of Nyxoah (NYXH) as follows:

**Strengths:** * The company passed the Debt Payback test, suggesting a specific metric regarding its debt timeline met the system's criteria. * The P/E valuation test was marked as passed, though the negative ratio requires careful interpretation.

**Weaknesses:** * **Profitability:** The company failed the EPS test, indicating a lack of consistent earnings. * **Capital Efficiency:** An ROIC of -98.81% indicates significant value destruction and inefficient use of capital. * **Solvency:** The failure of the interest coverage test suggests potential difficulty in meeting interest obligations from current earnings. * **Data Gaps:** Insufficient data for moving averages prevents any trend-based timing analysis.

Risks and Limitations

Investors should be aware of the inherent risks in medical device companies, particularly those with negative ROIC and failed interest coverage. These companies often face "uncertainty risk," where changes in government healthcare policy, regulatory shifts by the FDA, or increased competition can impact their ability to reach profitability. Furthermore, in an environment of fluctuating interest rates and government debt concerns, companies that struggle to cover their interest payments are at a higher risk of liquidity issues.

This research is limited by the data provided. It does not account for unannounced clinical trial results, pending patent litigation, or macro-economic shifts that could alter the company's trajectory.

Educational Conclusion

In summary, Nyxoah (NYXH) presents a profile characterized by significant financial challenges. With a StockValueFinder score of 33% and an "AVOID" rating, the quantitative data points to a company that is currently struggling with profitability (EPS), capital efficiency (ROIC), and interest obligations (Interest Coverage). While it passed certain debt-related tests, the overall picture is one of high financial risk.

By learning to identify these specific failures—such as a negative ROIC or failed interest coverage—investors can better protect their capital by avoiding companies that do not meet the fundamental requirements of stability and value.

This article is for research and educational purposes only. It is not personal financial advice, investment advice, or a recommendation to buy or sell any security.

Research links: Yahoo Finance | Seeking Alpha | Finviz | SEC Filings